Daewoong Pharmaceutical's own botulinum toxin drug "Nabota" is accelerating its global expansion.
Daewoong Pharmaceutical announced on April 30 that it has recently obtained a series of product licenses for Nabota's intramuscular wrinkle indication in Turkey and Chile.
Nabota is the first Korean botulinum toxin product to obtain an item license in Turkey and aims to be released within the third quarter.
Turkey is a key country connecting Asia and Europe, and Daewoong Pharmaceutical plans to accelerate its launch in Europe based on Nabota's entry into Turkey.
Chile is an advanced country in the beauty plastic surgery sector in Latin America, and this permit is expected to further strengthen Nabota's position in the Latin market.
Nabota has won product licenses in 10 Latin American countries, including Brazil, the largest market in Latin America, Mexico, Panama and Bolivia.
Nabota's Turkish sales will be handled by its local partner, SELTEK, and Chile's sales will be handled by Torregal.
SELTEK is the No. 1 filler company in Turkey and is exclusively supplying TEOSYAL to Turkey.
Torregal is an esthetic company that has established a solid sales network throughout Chile and is looking forward to Nabota's rapid development in the local market.
"Turkey and Chile are rapidly growing cosmetic surgery markets, and we expect this license to further strengthen Nabota's position as a global brand," said Park Sung-soo, head of Nabota Business Division at Daewoong Pharmaceutical. "We will further enhance K-Bio's status based on Nabota's excellent product capabilities proven in advanced countries."